Drawing for QVL MYSECURERX

USPTO serial 85521279

QVL MYSECURERX

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
BESCH, JAY C
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with QVL MYSECURERX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Carl C. Butzer

CARL C. BUTZER JACKSON WALKER L.L.P.901 MAIN ST STE 6000DALLAS, TX 75202-3797UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
035Retail pharmacy prescription services, namely, processing online and telephone prescription orders in retail and central fill pharmaciesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Nov 12, 2013MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 11, 2013ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 8, 2013EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 7, 2013EX1GSOU EXTENSION 1 GRANTED—
Apr 30, 2013AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Apr 8, 2013EXT1SOU EXTENSION 1 FILED—
Apr 8, 2013EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 9, 2012NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Aug 24, 2012ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
Apr 10, 2012ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Apr 10, 2012NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 10, 2012PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 21, 2012NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 6, 2012PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Mar 2, 2012ALIEASSIGNED TO LIE—
Feb 14, 2012CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 14, 2012XAECEXAMINER'S AMENDMENT ENTERED—
Feb 14, 2012GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Feb 14, 2012GNEAEXAMINERS AMENDMENT E-MAILED—
Feb 14, 2012CNEAEXAMINERS AMENDMENT -WRITTEN—
Feb 14, 2012DOCKASSIGNED TO EXAMINER—
Jan 26, 2012MPMKNOTICE OF PSEUDO MARK MAILED—
Jan 25, 2012NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 24, 2012NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance